249 related articles for article (PubMed ID: 34799729)
21. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
Huang GL; Shen DY; Cai CF; Zhang QY; Ren HY; Chen QX
World J Gastroenterol; 2015 Jan; 21(4):1148-57. PubMed ID: 25632187
[TBL] [Abstract][Full Text] [Related]
22. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
[TBL] [Abstract][Full Text] [Related]
24. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
25. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.
Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S
J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393
[TBL] [Abstract][Full Text] [Related]
26. Novel Targeted Therapies for Advanced Cholangiocarcinoma.
Rizzo A; Brandi G
Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652960
[TBL] [Abstract][Full Text] [Related]
27. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
Izquierdo-Sanchez L; Lamarca A; La Casta A; Buettner S; Utpatel K; Klümpen HJ; Adeva J; Vogel A; Lleo A; Fabris L; Ponz-Sarvise M; Brustia R; Cardinale V; Braconi C; Vidili G; Jamieson NB; Macias RI; Jonas JP; Marzioni M; Hołówko W; Folseraas T; Kupčinskas J; Sparchez Z; Krawczyk M; Krupa Ł; Scripcariu V; Grazi GL; Landa-Magdalena A; Ijzermans JN; Evert K; Erdmann JI; López-López F; Saborowski A; Scheiter A; Santos-Laso A; Carpino G; Andersen JB; Marin JJ; Alvaro D; Bujanda L; Forner A; Valle JW; Koerkamp BG; Banales JM
J Hepatol; 2022 May; 76(5):1109-1121. PubMed ID: 35167909
[TBL] [Abstract][Full Text] [Related]
28. Role of molecular genetics in the clinical management of cholangiocarcinoma.
Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs.
Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E
Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404
[TBL] [Abstract][Full Text] [Related]
32. Cholangiocarcinoma miscoding in hepatobiliary centres.
Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
[TBL] [Abstract][Full Text] [Related]
33. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress.
Gadaleta-Caldarola G; Rizzo A; Dadduzio V; Lombardi L; Gadaleta-Caldarola A; Infusino S; Cusmai A; Citrigno C; Palmiotti G
Curr Oncol; 2022 Oct; 29(10):7925-7931. PubMed ID: 36290903
[TBL] [Abstract][Full Text] [Related]
34. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
Loilome W; Namwat N; Jusakul A; Techasen A; Klanrit P; Phetcharaburanin J; Wangwiwatsin A
Recent Results Cancer Res; 2023; 219():53-90. PubMed ID: 37660331
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
[TBL] [Abstract][Full Text] [Related]
36. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
Uson Junior PLS; Borad MJ
Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
[TBL] [Abstract][Full Text] [Related]
37. Pathologic classification of cholangiocarcinoma: New concepts.
Nakanuma Y; Kakuda Y
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma.
Shen DY; Zhang W; Zeng X; Liu CQ
Cancer Sci; 2013 Oct; 104(10):1303-8. PubMed ID: 23822562
[TBL] [Abstract][Full Text] [Related]
39. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450
[TBL] [Abstract][Full Text] [Related]
40. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
